Outlook Therapeutics FY2025 net loss $62.4M; $1.4M revenue from LYTENAVA launch in Europe

Outlook Therapeutics, Inc.

Net loss $62.4M ($1.79/share) vs $75.4M ($4.06/share) prior year; revenue $1.4M from initial EU sales.
Cash $8.1M at Sept 30, 2025; $14.9M net from ATM after quarter-end; no debt mentioned.
Expenses fell $4.6M YoY due to lower R&D, partly offset by higher SG&A for European launch.
FDA PDUFA goal date for ONS-5010 is Dec 31, 2025; awaiting U.S. approval decision.
LYTENAVA accepted into UK tender framework in Dec 2025; launch expanding to Austria and Netherlands.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-122786
form_type: 8-K
ticker: OTLK
cik: 0001649989
company_name: Outlook Therapeutics, Inc.
filed_at: 2025-12-19T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.043989+00:00
generated_at: 2026-05-16T12:34:59.647316+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: negative
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-122786
json_url: https://secwatch.observer/filing/0001104659-25-122786.json
markdown_url: https://secwatch.observer/filing/0001104659-25-122786.md
text_url: https://secwatch.observer/filing/0001104659-25-122786.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/0001104659-25-122786-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-25-122786

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.